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Summary 
Introduction: Although experimental studies demonstrated that platelets are pro-
inflammatory cells, no randomized studies tested the anti-inflammatory effect of 
antiplatelet agents in humans. The platelet P2Y12 receptors mediated bronchial 
inflammation in a mouse model of asthma, suggesting that P2Y12 represents a 
pharmacological target for asthma. Objectives: In this proof-of concept, placebo-
controlled, randomized, cross-over study we tested the effects of the P2Y12 antagonist 
prasugrel on bronchial hyper-reactivity of asthmatic patients. Patients/Methods: 
Twenty-six asthmatic patients were randomly and blindly allocated to prasugrel (10mg 
o.d.) or placebo for 15 days. After ≥15-day wash-out, patients were crossed-over to the 
alternative treatment. Before and after each treatment, patients underwent bronchial 
provocation test with mannitol and measurement of fractional exhaled nitric oxide 
(FeNO).  Inhibition of P2Y12-dependent platelet reactivity (PRI) was measured by the 
VASP phosphorylation assay. Results: The provocative dose of mannitol causing a 
15%-drop in FEV1 tended to increase from 142 mg (95%CI 82-202) to 187 mg (113-
262)  after prasugrel (p=0.09) and did not change after placebo (136 mg; 76-196 and 
144 mg; 84-204 , p=0.65). FeNO did not change after either treatment. PRI decreased 
from 80%(77-83) to 23%(7-29) after prasugrel (p<0.001) and remained unchanged after 
placebo. Conclusions: Our proof-of-concept, randomized, controlled study is the first 
one to test in vivo the anti-inflammatory effects of platelet inhibition in human patients. 
Its results suggest that pharmacological inhibition of P2Y12 receptors may slightly 
reduce the bronchial inflammatory burden and lays the groundwork for further studies, 
with clinical end-points.   
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1.1 Asthma 
 
1.1.2 Definition of asthma 
Asthma is a heterogeneous disease, usually characterized by chronic airway 
inflammation. It is defined by the history of respiratory symptoms such as wheezing, 
shortness of breath, chest tightness and cough that vary over time and in intensity, 
together with variable expiratory airflow limitation.  
1.1.2 Description of asthma 
Asthma affects people of all ages, but it most often starts during childhood. Asthma 
is characterized by variable symptoms of wheezing, shortness of breath, chest tightness 
and/or cough and variable expiratory airflow limitation. Symptoms and airflow 
limitation vary over time and in intensity. These variations are often triggered by factors 
such as exercise, allergen, or irritant exposure, change in weather, or respiratory 
infections. Symptoms and airflow limitation may resolve spontaneously, or in response 
to medication and may sometimes be absent for weeks or months at a time. Patients can 
experience a minor inconvenience, while for others asthma can be a major problem that 
interferes with daily activities and may lead to life-threatening exacerbations. Asthma is 
usually associated with airway hyperresponsiveness to direct or indirect stimuli, and 
with chronic airway inflammation. 
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 Asthma phenotype: 
Asthma symptoms range from minor to severe and vary from person to person. 
Some patients have infrequent asthma attacks, have symptoms only at certain times, 
such as when exercising, or have symptoms all the time (1-3). 
For some people, asthma symptoms flare up in certain situations: 
• Exercise-induced asthma, which may be worse when the air is cold and dry 
• Occupational asthma, triggered by workplace irritants, such as chemical fumes, 
gases or dust 
• Allergy-induced asthma, triggered by particular allergens, such as pet, dander, 
cockroaches or pollen 
Asthma signs and symptoms include: 
• Shortness of breath 
• Chest tightness or pain 
• Trouble sleeping caused by shortness of breath, coughing or wheezing 
• A whistling or wheezing sound when exhaling  
• Coughing or wheezing attacks that are worsened by a respiratory virus, such as a 
cold or the flu 
1.1.3 Asthma diagnosis 
The first step in diagnosing asthma (4) is to identify patients at risk of, or with 
significant likelihood of having chronic airways disease and to rule out other possible 
conditions, such as a respiratory infection or chronic obstructive pulmonary disease 
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(COPD). This first step is based on a detailed medical history and physical examination. 
A diagnosis of asthma should be suspected if there is a history of: recurrent wheezing, 
coughing or difficulty breathing and these symptoms occur or worsen due to exercise, 
viral infections, allergens or air pollution. The diagnosis of allergic asthma is more 
likely when the person also has an allergy and a family history of asthma. 
Tests to measure lung function 
• Spirometry (5). This test estimates the narrowing of bronchial tubes by checking 
how much air can be exhaled after a deep breath and how fast it can be breathed out. 
• Methacholine challenge (6, 7). Methacholine is a known asthma trigger that, 
when inhaled, will cause mild constriction of airways. The methacholine challenge 
involves the inhalation of increasing concentrations of this substance that causes airway 
narrowing in those predisposed. If negative it means that a person does not have asthma; 
if positive, however, it is not specific for the disease 
• Nitric oxide test (8). This test measures the amount of the gas, nitric oxide, that 
patients have in their breath. When airways are inflamed, a sign of asthma, patients may 
have higher than normal nitric oxide levels. 
Other tests include: 
• Allergy testing. This can be performed by skin test or blood test. Allergy tests 
can identify allergy to pets, dust, mold and pollen. If important allergy triggers are 
identified, this can lead to a recommendation for allergen immunotherapy. 
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• Sputum eosinophils. This test looks for certain white blood cells (eosinophils) in 
the mixture of saliva and mucus (sputum) which patients discharge during coughing. 
Eosinophils are present when symptoms develop and become visible when stained with 
a rose-colored dye (eosin).  
• Imaging tests. A chest X-ray and high-resolution computerized tomography (CT) 
scan of lungs and nose cavities (sinuses) can identify any structural abnormalities or 
diseases (such as infection) that can cause or aggravate breathing problems. 
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1.2 Platelets 
1.2.1 Platelet biology 
Platelets are small anuclear blood cells, with a discoid shape ranging between 1 
to 3 µm in diameter. These cell fragments originate from the cytoplasm of 
megakaryocytes (MKs) in the bone marrow and circulate in the human bloodstream for 
about 10 days. Platelets lack genomic DNA (9) but contain megakaryocyte-derived 
messenger RNA (mRNA) and the translational machinery needed for protein synthesis 
including ribosomes, and initiation and termination factors (10). Furthermore, platelets 
contain three types of secretory organelles known as α-granules, δ-granules (dense) and 
lysosomes, which are generated by the budding of small vesicles containing granule 
cargo from the trans-Golgi zone of the Golgi complex in MKs (11). The number of α-
granules per platelet depends on cell size and may range between 40 and 80. They 
contain many proteins, such as coagulation factor V, thrombospondin, P-selectin, von 
Willebrand Factor (vWF) and fibrinogen. The δ-granules, compared with α-granules, 
are smaller, fewer, and have high morphological variability. They are rich in ATP and 
ADP, serotonin, pyrophosphate, calcium, and magnesium. Human platelets also contain 
few lysosomes (no more than 3), which contain at least 13 acid hydrolases. Other 
organelles present in the platelet cytoplasm include a small number of simple 
mitochondria involved in energy metabolism, glycosomes (12), electron dense chains 
and clusters (13), and tubular inclusions (14).  
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1.2.2 Platelets in primary hemostasis 
 
The main role of blood platelets is to ensure primary hemostasis, which means 
the rapid cessation of bleeding after tissue trauma and the maintenance of the integrity 
of the endothelium, in part through the release of proangiogenic cytokines and growth 
factors. The balance between blood fluidity and rapid thrombus formation in response to 
injury is regulated by endothelial cells, which synthesize either inhibitors or activators 
of platelet aggregation and blood clotting (15, 16). Under normal physiological 
conditions, platelets circulate close to the endothelium without establishing/ forming 
stable adhesion contacts. The anti-adhesive phenotype of vascular endothelium cells 
towards platelet is maintained by at least 4 intrinsic pathways. The arachidonic acid-
prostacyclin (PGI2) and the L-arginine-nitric oxide (NO) pathways inhibit platelet 
activation by the stimulation of cAMP and cGMP production respectively, whereas 
endothelial ecto-adenosine diphosphatase (ecto-ADPase/CD39) is involved in ADP 
metabolism, which is necessary to prevent premature platelet activation at the vessel 
wall. Furthermore, thrombomodulin rapidly inhibits the prothrombotic effect of α 
thrombin, reducing platelet activation and fibrin generation (Figure 1).  
At sites of vascular injury, platelets interact with the damaged vessel, to form a 
platelet aggregate. The initial platelet tethering at the surface and subsequent platelet-
platelet cohesion are typically differentiated into the following steps: adhesion, 
activation, secretion and aggregation of platelets (17).  
 Platelet Adhesion 
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After vascular injury, such as rupture or erosion of the vessel wall, subendothelial 
matrix proteins such as collagen, von Willebrand factor (vWF), fibronectin and laminin 
become exposed to the circulating blood. These proteins support platelet adhesion via 
the engagement of specific receptors, thus rapidly recruiting individual platelets at the 
site of subendothelial damage. The initial tethering of platelets occurs via the interaction 
between glycoprotein Ib (GPIb), a component of GPIb-V-IX platelet complex, and 
exposed collagen-bound vWF. This bond has a rapid dissociation rate and is therefore 
unable to support stable adhesion, resulting in platelet translocation along the vessel 
wall. Translocating platelets engage with collagen in the vessel wall through their 
adhesion receptors glycoprotein VI (GPVI) and GPIa. GPVI is the major collagen 
receptor, whose stimulation induces the intracellular calcium flux necessary for stable 
platelet adhesion, cytoskeletal reorganization, integrin glycoprotein IIb/IIIa (αIIbβ3) 
activation and the release of soluble agonists.  
 Platelet Activation and Secretion 
After the initial adhesion, platelets undergo the repair process that requires a quick 
response to autocrine and paracrine mediators. Platelets experience a complex series of 
morphological and biochemical changes that lead to the release of platelet granular 
content such as ADP and serotonin (5-HT), as well as to the synthesis of TxA2. These 
endogenous agonists act to enhance platelet activation by interacting with specific G-
protein coupled receptors expressed on the platelet membrane. Briefly, ADP and 5-HT 
are released from platelet dense granules and bind their specific receptors. Activation of 
the 5-HT2A receptor by 5-HT and the P2Y1 receptor by ADP (both coupled to a Gq 
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protein) induces an increase in intracellular Ca2+ levels, whereas activation of P2Y12 
(couple to Gi protein) by ADP activates PI3kinase and inhibits adenylate cyclase. TxA2 
is synthesized in activated platelets starting from arachidonic acid (AA) by 
cyclooxygenase (COX). Once formed, TxA2 diffuses across the platelet membrane and 
activates other platelets through the interaction with two surface membrane TxA2 
receptors, TPα and TPβ, coupled to the proteins Gq and G12 or G13, which activate 
phospholipase C (PLC). This enzyme degrades membrane phospholipids, thus releasing 
secondary messengers inositol triphosphate (IP3) and diacylglycerol (DAG). DAG 
activates intracellular protein kinase C (PKC), which causes protein phosphorylation, 
whereas IP3 increases cytosolic Ca2+ levels from the endoplasmic reticulum. In 
addition platelets provide a catalytic surface necessary for local production of thrombin 
thus enhancing platelet activation. Indeed, at the site of injury prothrombin is 
proteolytically cleaved to form thrombin, a serine protease that converts soluble 
fibrinogen into insoluble strands of fibrin. Subsequently, thrombin mediates cleavage of 
the N-terminal extradomain of protease-activated receptors (PAR)-1 and (PAR)-4, that 
increases intracellular calcium (Ca2+). The generation of thrombin is contingent upon 
the expression of tissue factor (TF) on the surface of fibroblasts, smooth muscle cells, 
endothelial cells and leukocytes. Thrombin is among the most potent stimulators of 
platelets. 
 Platelet Aggregation 
Aggregation is the amplification step that involves accumulation of platelets into 
the hemostatic thrombus through release of soluble agonists that enhance recruitment of 
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further platelets. The stimulation of Gq and Gi signaling pathways leads to activation of 
the glycoprotein complex GPIIb/IIIa. Activated GPIIb/IIIa binds multiple ligands, 
including vWF (18, 19), fibrinogen (20), fibrin and fibronectin (21), able to form stable 
platelet aggregates (22). The primary hemostatic plug is consolidated by fibrin 
generation at the site of injury. Platelet activation is under tight negative control to limit 
and contain thrombus formation within the boundaries of the lesion in the vessel wall. 
 
Figure 1. Modified from (23) The antiadhesive phenotype of endothelial cells is maintained through four 
intrinsic pathways: ecto-ADPase, prostaglandin I2 (PGI2), nitric oxide (NO) and the thrombomodulin 
(TM)-activated protein C (APC) pathways. 
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1.2.3 Role of platelets in arterial thrombosis and atherosclerosis 
Arterial thrombosis and atherosclerosis have been considered separate entities 
with different pathogenic mechanisms, natural histories and therapies. Arterial 
thrombosis is primarily mediated by platelets and fibrin (24), whereas pathogenesis of 
atherosclerosis is multifactorial but is mainly promoted by altered function of 
endothelial and smooth muscle cells, deposition of lipids metabolized abnormally and 
oxidized in the vascular wall, and the local infiltration of leukocytes (25, 26). However, 
it is becoming clear that the cellular and biochemical interactions underlying thrombosis 
are also directly relevant to atherosclerosis (27). 
Arterial thrombosis 
Arterial thrombosis is an acute complication that occurs after rupturing or erosion of 
unstable atherosclerotic plaque in the blood vessels. In the case of coronary heart 
disease it causes heart attack, whereas in the case of cerebrovascular disease it leads to 
stroke. The most abundant components of the occlusive arterial thrombi formed   are 
platelets with fibrin. On the other hand, platelets seem to be less relevant in the 
pathogenesis of venous thromboembolism.  
Platelet thrombus formation is thought to occur in successive stages. After vascular 
injury, under conditions of rapid blood flow that occur in stenotic diseased arteries, 
platelets adhere to the exposed subendothelium (platelet adhesion), are activated 
(platelet activation) and secrete their granule contents (platelet secretion), including 
some platelet agonists (ADP and serotonin) which contribute to the recruitment of 
additional platelets to form aggregates (platelet aggregation) by interacting with specific 
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platelet receptors. In this pathological condition the mechanism supporting platelet 
adhesion and aggregation at the site of vascular injury follows the physiological 
processes previously described in the paragraph 1.2.2. 
Atherosclerosis 
Atherosclerosis is in part an inflammatory disease, affecting medium and large 
size arteries through the accumulation of fatty substances, cholesterol, cellular waste 
product, calcium and fibrin within the arterial intima resulting in atherosclerotic plaques. 
Atherosclerosis starts when these deposits (plaque) lead to the inner surface of the blood 
vessel becoming damaged and the narrowing of the lumen, making it harder for blood to 
flow through. Plaques may induce partial or total obstruction of blood flow through the 
artery (stenosis) and in the case that a piece of the plaque breaks off, trigger the 
formation of a blood clot (thrombus), causing heart attack or stroke. 
Several factors promote the process of atherosclerosis, they are known as risk factors 
and include (28): 
 Cigarette smoke 
 Decreased physical activity 
 Consumption of unhealthful foods (rich in salt, fat and calories) 
 Harmful use of alcohol 
 High blood pressure (hypertension) 
 Diabetes 
 High levels of cholesterol and triglycerides 
 Overweight and obesity 
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 Male gender 
 Genetic disposition 
 Psychological factors (e.g. stress, depression) 
 Other risk factors (e.g. excess homocysteine) 
Platelets play a central role in arterial thrombosis but may also participate in the 
development and progression of atherosclerotic plaque. Platelets promote the 
progression of plaque formation by forming platelet/leukocyte aggregates and via 
adhesion to the endothelium. Specific pro-inflammatory signals make endothelial cells 
more adhesive toward platelets, stimulating the production of various platelet-derived 
inflammatory molecules that provide a positive feedback loop for the activation of 
further endothelial cells. Indeed, under inflammatory conditions platelets can adhere to 
the intact but activated endothelial cells (29-31). Additionally an increase of circulating 
activated platelets promotes atherosclerosis. Endothelial-bound platelets are highly 
effective at recruiting leukocytes from flowing blood and also enhance leukocyte 
adhesion and transmigration to the site of the proinflammatory stimulus.  
Activated-platelets induce shorter plaque formation by releasing and exposing P-
selectin on plasma membrane, which binds to the P-selectin glycoprotein ligand 1 
(PSGL-1) receptor on monocyte cell surface, thus forming platelet-monocyte aggregates. 
Once activated, platelets are capable of time-dependent synthesis of protein mediators, 
such as interleukin-1β, which cause an increase in the release of chemokines and up-
regulate molecules that promote adhesion of neutrophils and monocytes to the 
endothelium (32). Another important mediator released from platelets is the CD40 
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ligand which triggers an inflammatory response of the endothelial cells (33). This ligand 
is stored in α-granules of resting platelets and becomes rapidly exposed on cell surface 
following platelet activation (34). CD40 ligand undergoes cleavage over a period of 
minutes to hours, generating a functional soluble fragment. The soluble CD40 ligand is 
released into the extracellular environment inducing endothelial cells to produce 
reactive oxygen species (35), adhesion molecules, chemokines(33), and tissue factor (36) 
leading to an inflammatory response. The interaction between platelets, endothelial cells 
and leukocytes thus establishes a localized inflammatory response that can accelerate 
the early formation of atherosclerosis lesions. In addition platelets release platelet-
derived growth factor (PDGF), which stimulates smooth muscle proliferation and 
angiogenesis in the plaque (37). 
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1.3 The platelet P2Y12 receptor for adenosine diphosphate  
 
1.3.1 ADP pathway  
Adenosine diphosphate (ADP), the first known low molecular weight platelet 
aggregating agent, plays an important role in platelet function despite being a weak 
platelet agonist. As such, it only induces platelet shape change and reversible 
aggregation in humans. Platelet secretion and secondary aggregation observed after 
stimulation with ADP of normal, human citrated platelet-rich plasma are due to the 
aggregation-dependent formation of TxA2. ADP is released in high concentration from 
platelet dense granules where it is stored and amplifies platelet responses induced by 
other agonists (38, 39) and stabilizes platelet aggregate (40, 41). ADP stimulates two 
specific G protein coupled P2 receptors on the platelet surface. The transduction of its 
signal involves both a transient rise in free cytoplasmic calcium, mediated by the Gq-
linked P2Y1 receptor, and inhibition of adenylyl cyclase, which is mediated by the Gi-
linked P2Y12 receptor (42). The activation of P2Y1 receptor by ADP mediates platelet 
shape change and initiates platelet aggregation, whereas P2Y12 amplifies the platelet 
aggregation response (43). Concomitant activation of both G protein-coupled receptors 
is essential to elicit normal platelet aggregation (42, 44) (Figure 2) 
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Figure 2. Figure modified from (45). Role of P2Y12 in platelet aggregation. ADP interact with P2Y12, a 
seven-transmembrane receptor that is coupled to Gi protein. This bond induces platelet aggregation and 
amplifies the aggregation response that is induced by other agonists or by ADP itself, by interacting with 
its other platelet receptor, P2Y1. P2Y12 stabilizes platelet aggregates and amplifies the secretion of 
platelet dense granules stimulated by secretion-inducing agonists (coupled to Gq). P2Y12 is coupled to 
inhibition of adenylyl cyclase (AC) through Gi, this function does not appear to be directly related to 
P2Y12 -mediated platelet activation. However, it could have important implications in vivo, where 
platelets are exposed to the inhibitory prostaglandin PGI2 (prostacyclin), which inhibits platelet 
aggregation by increasing platelet cyclic adenosine monophosphate (cAMP) through activation of AC 
mediated by Gs: inhibition of AC by P2Y12 counteracts the inhibitory effect of prostacyclin, thereby 
favoring the formation of platelet aggregates in vivo. 
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1.3.2 P2Y12 receptor 
The P2 receptors, which interact with purine and pyrimidine nucleotides, are 
divided into two groups: G protein-linked or metabotropic, termed P2Y, and ligand-
gated ion channels or ionotropic, termed P2X (46). The P2Y receptors are seven-
membrane-spanning proteins with a molecular mass of 41 to 53 kD after glycolysation 
(46). The carboxyl terminal domain is on the cytoplasmatic side, whereas the amino 
terminal domain is exposed to extracellular environment. The mechanisms of signal 
transduction are shared by most seven-membrane-spanning receptors, and include 
activation of phospholipase C and regulation of adenylyl cyclase activity. The Gq 
coupled receptor P2Y1 leads to activation of β-isoforms of phospholipase C (PLC) and 
triggers the mobilization of Ca
2+
 into the cytoplasm. The Gi coupled receptor P2Y12 
leads to inhibition of adenyl cyclase (AC) with an increase of platelet cyclic adenosine 
monophosphate (cAMP). Co-interaction of the P2Y1 and P2Y12 is necessary for normal 
ADP-induced platelet aggregation, in fact separate inhibition of either of them with 
selective antagonists results in a dramatic decrease in aggregation (44, 47, 48). The 
stimulation of the ADP receptors, predominately the P2Y12 receptor, assists to 
activation of integrin GP IIb/IIIa (fibrinogen receptor)(49, 50). P2Y12 is important for 
both normal hemostasis and pathologic thrombosis result this receptor is relevant target 
for antiplatelet drug and research is very interested in this field. 
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1.4 Antiplatelet drugs: ADP/ P2Y12 antagonists 
 
Thienopyridines (ticlopidine, clopidogrel and prasugrel) irreversibly inhibit 
P2Y12, while ticagrelor and cangrelor are reversibly-binding inhibitors (51, 52). 
1.4.1 Clopidogrel 
 
Pharmacology 
 
(+)-(S)-methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate 
Molecular mass: 321.82 g/mol 
Figure 3. Chemical structure of clopidogrel 
 
Ticlopidine and Clopidogrel are structurally related compounds, but ticlopidine 
has been almost completely replaced by clopidogrel in clinical practice, due to the its 
cytotoxicity (neutropenia, thrombotic thrombocytopenic purpura). In fact, clopidogrel 
resulted a better tolerated and safer drug than ticlopidine. Clopidogrel is absorbed as a 
pro-drug in the intestine and then modified via two competing pathways in the liver. In 
one, clopidogrel is rapidly metabolized by human carboxylesterase 1 (hCE1) to an 
inactive acid metabolite (53), about 75% of clopidogrel administrated is converted 
through this step (54). In the second pathway, clopidogrel is metabolized in a two-step 
process, first to 2-oxo-clopidogrel by CYP2C19, CYP1A2 and CYP2B6, subsequently 
into the active metabolite by CYP2B6, CYP3A2, CYP2C9 and CYP2C19 and in 
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inactive acid metabolite of 2-Oxo-Clopidogrel by esterase (53). The active metabolite 
irreversible binds to P2Y12 by forming a covalent disulfide bond with cysteine residues. 
The consequence of an irreversible inhibition is that stays on for entire life span of 
circulating platelets (55). Gastrointestinal side effects are also described during 
treatment with clopidogrel, even if clinically less severe than in aspirin-treated patients 
(56). 
Despite its proven antithrombotic efficacy clopidogrel has some important limitations: 
1. The need for metabolism to active metabolite causes a delayed antiplatelet 
effect, with a maximum plateau of inhibition of ADP-induced platelet 
aggregation from 4 to 5 days after daily dose of 75 mg of clopidogrel. However, 
the delayed of action of clopidogrel can be reduced to approximately 2-5 hours 
by a loading dose of 300-600 mg (57, 58).  
2. There is interindividual variability in the response to clopidogrel, which is due 
mostly to interindividual differences in the extent of metabolism of the prodrug 
in the liver (mutation of CYP2C19 and other CYP isoform)(59, 60). 
Furthermore, the variables that can affect the pharmacodynamics response to 
clopidogrel are several as lack of compliance, reduced absorption, interaction 
with other drugs, age, high body mass index, diabetes mellitus, renal 
insufficiency in diabetes mellitus, pre-existed variability in platelet response to 
ADP, increased platelet turnover, tobacco smoking.  
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1.4.2 Prasugrel 
 
Pharmacology 
OH
O
O
F
SH
N
 
2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetra-hydrothieno[3,2-c]pyridine;  
Molecular mass: 349.42; 
Figure 4. Chemical structure of prasugrel (61) 
 
Prasugrel is a thienopyridyl pro-drug that is rapidly metabolized to its active 
metabolite R-138727 (Figure 4) and irreversibly inhibits platelet P2Y12 receptors. Oral 
administration of prasugrel is 10 and 100 times more effective on an equal-dose on 
inhibition of platelet aggregation than clopidogrel and ticlopidine, respectively (62), 
although the active metabolites for prasugrel and clopidogrel have equipotency at the 
P2Y12 receptor in vitro (63). In addition, prasugrel has a more rapid onset of action than 
clopidogrel and is less dependent to CYP enzyme than clopidogrel, as has a distinct 
chemical structure that allows a more efficient conversion to its active metabolite. The 
biotrasformation of prasugrel to its active metabolite, 2-[1-[2-cyclopropyl-1-(2-
fluorophenyl)-2-oxoethyl]-4-mercapto-3-piperidinylidene] acetic acid, requires ester 
bond hydrolysis by carboxylesterase (hCE)-2 in the intestine (61, 64) forming the 
thiolactone, and then an oxidation by intestinal and hepatic cytochrome P450–mediated, 
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mainly CYP3A and CYP2B6 (65), with smaller contributions by CYP2C9 and 
CYP2C19 (65).  
The different pharmacokinetics and pharmacodynamics of prasugrel compared with 
clopidogrel can be summarized as follows (66):  
1. fast appearance of its active metabolite in circulating blood within 15 minutes 
of dosing, which reaches maximal plasma concentration at ≈30 minutes;  
2. higher mean area under the concentration-time curve of the active metabolite of 
prasugrel 60 mg than that of clopidogrel 600 mg;  
3. faster and greater mean inhibition of P2Y12-dependent platelet function after a 
60-mg loading dose and 10-mg maintenance dose than after a 300- or 600-mg 
loading dose and 75- or 150-mg maintenance dose of clopidogrel;  
4. no influence of the CYP genotype on its pharmacokinetics and 
pharmacodynamics;  
5. much lower interindividual variability in the inhibition of P2Y12-dependent 
platelet responses and extremely low prevalence of subjects who display 
resistance to prasugrel. 
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1.4.3 Ticagrelor 
 
Pharmacology 
 
 
(1S,2S,3R,5S)-3-[7-{[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino}-5-(propylthio)- 
3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol. 
Molecular mass = 522.57; 
Figure 5. Chemical structure of ticagrelor. 
 
Ticagrelor (previously known as AZD6140) belongs to a new chemical class of 
compounds, the cyclopentyl-triazolo-pyrimidines, which target the P2Y12 receptor 
(Figure 5) (67, 68). It is the first reversibly binding oral P2Y12 receptor antagonist with 
a pIC50 value of 7.9 for inhibition of 30 µM ADP-induced aggregation of human-
washed platelets and no significant affinity for other P2 receptor at concentrations >3 
µM (67).  
In contrast to the other antiplatelet drugs, ticagrelor appears to inhibit P2Y12 
receptor in a noncompetitive manner suggesting the existence of an independent 
receptor binding site, making it an antagonist (52). The drug does not need activation 
whereby the pharmacological effect of ticagrelor is not influenced by CYP genotypes. It 
N
N
N
N
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gives a more complete and consistent platelet inhibition compared to clopidogrel (69). 
Ticagrelor has a rapid beginning of action, reaching maximal inhibition of platelet 
function in about 2 hours (70, 71). Although the plasma half-life of ticagrelor is 6-8 
hours (70, 72), the duration of its inhibitory effect is much longer, because platelet 
function returns to near normal levels after about 5 days following cessation of 
treatment (73). Ticagrelor has been shown to inhibit erythrocyte adenosine uptake likely 
via the equilibrative nucleoside transporter 1 (ENT1) (74) and to augment adenosine-
induced coronary blood flow, possibly contributing to reduced myocardial infarction 
size (75).  
Briefly, ticagrelor has the potential to address many of the limitations of thienopyridine 
therapy:  
1. is not a prodrug and therefore does not require metabolic activation, has a rapid 
and reversible concentration dependent inhibitory effect on the P2Y12 receptor;  
2. provides greater and more consistent inhibition of ADP-induced platelet 
aggregation than clopidogrel; 
3. offers the potential for greater flexibility in the management of patients at risk 
for thrombotic events due to rapid onset and offset of antiplatelet effect;  
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1.5 The role of platelets P2Y12 receptor in inflammation and asthma 
 
In addition to their well characterized and established role in hemostasis and 
thrombosis, platelets also have inflammatory functions and influence innate and 
adaptive immune responses (76-78). They express toll-like receptors, interact with 
activated endothelium, undergo chemotaxis, “prime” leukocytes for efficient tissue 
recruitment, activate other inflammatory cells, exert phagocytosis, release biologically 
active substances, including adhesive proteins, vasoactive and pro-inflammatory 
mediators(76-78). 
Allergic bronchial asthma is a chronic inflammatory disease that impairs the quality of 
life, is associated with significant mortality rate and negatively impacts on health care 
and social costs. In1981, it was shown that platelets are activated during antigen-
induced bronchoconstriction (79). More recently, it was shown that pplatelets 
accumulate in lungs of asthmatic patients, are required for airway wall remodelling and 
recruitment of inflammatory cells in murine allergic lung inflammation (80, 81) and 
migrate into the lungs of ovalbumin-sensitized and -challenged mice by an IgE-
dependent mechanism(82). 
Cysteinyl-leukotrienes (LTs) LTC4, LTD4 and LTE4 are biologically active lipids that 
play a role in allergic asthma (83). They are formed in eosinophils, basophils and mast 
cells by 5-lipoxygenase, which catalyses the conversion of arachidonic acid into LTA4, 
an unstable intermediate that is enzymatically converted into either LTB4 or LTC4, 
which is transported into the extracellular space where a gamma-glutamyl-
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transpeptidase forms LTD4, which is finally converted into the stable metabolite LTE4 
(84. Cysteinyl-LTs interact with G protein-coupled receptors, CysLT1R, CysLT2R and 
GPR99 {Hui, 2001 #10, 85, 86). Platelets adhere to leukocytes and amplify the 
production of Cysteinyl-LTs (83), express CysLT1R and CysLT2R and, when exposed 
to LTD4 or LTE4, release RANTES, a powerful eosinophil chemoattractant (87). 
In the last few years, the pro-inflammatory role of adenine nucleotides interacting with 
their platelet P2 receptors has emerged. In particular, it was shown that the platelet 
P2Y12 receptor for ADP significantly contributed to the pro-inflammatory effects of 
cysteinyl leukotrienes (CysLT) in experimental models of asthma in mice. LTE4 
enhances inflammatory cell recruitment in lungs of sensitized mice, which is abrogated 
by platelet depletion, by treatment with the anti-P2Y12 thienopyridine drug clopidogrel, 
and in mice lacking P2Y12, but not in mice lacking CysLT1R and CysLT2R (88). 
Moreover, intranasal administration of LTC4 in sensitized mice before ovalbumin 
challenges potentiated the recruitment of eosinophils in the bronchoalveolar lavage, 
which was dependent on CysLT2R, on P2Y12 and platelets (89). Therefore, the platelet 
P2Y12 may represent an ideal pharmacological target for the treatment of allergic 
asthma. 
Despite the profusion of experimental studies demonstrating the role of platelets in 
inflammatory diseases in general and in allergic asthma in particular, no randomized, 
controlled study tested whether inhibition of platelet function has beneficial effects in 
patients with inflammatory diseases.  
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2. AIM OF THE STUDY 
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The aim of the study was to test whether or not inhibition of the platelet P2Y12 
receptor by the P2Y12 antagonist prasugrel (66) reduces bronchial hyper-reactivity in 
patients with asthma: “PRasugrel IN Asthma” (PRINA), a proof-of-concept randomized, 
double-blind, cross-over, placebo-controlled study.  
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3. MATERIALS AND METHODS 
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3.1  Study design 
 
Randomized, double blind (Subject, Caregiver, Investigator, Outcomes 
Assessor), cross-over, placebo-controlled, prospective study. The study was approved 
by the Ethical Committee of Ospedale San Paolo, Milan, Italy and was conducted in 
agreement with the principles of the Helsinki Declaration. All patients gave their written 
informed consent to the study. Randomization was performed in sequential blocks. 
Patients were blindly and randomly allocated to treatment “A” (placebo) or “B” 
(prasugrel 10 mg o.d., Efient, Eli Lilly and Daiichi-Sankyo) for 15 days. After ≥15 days 
wash-out, patients who had been allocated to treatment “A” were allocated to treatment 
“B”, and viceversa (Figure 6). Measurements were done at baseline and on day 15 after 
each treatment, at the same time (+/-1 h) of the day. Primary end-point was variation in 
airway hyper-responsiveness, recorded as reduction of FEV1 with the mannitol test; 
secondary end-points were variations in nitric oxide expiration and in inflammatory 
markers in sputum.  
The study is registered with ClinicalTrials.gov, number NCT01305369; EudraCT 
number: 2010-023945-31. 
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Figure 6. Schematic representation of the study design and diagram of enrolled patients. Prasugrel was 
given at 10 mg o.d. 
 
3.2 Study Patients 
 
Patients (18-74 years) with mild and stable asthma of  >1 year duration, without 
chronic medication, except for the use of inhaled beta2-agonists on demand, or low-
dose inhaled steroids, with positive mannitol bronchial challenge test were eligible. All 
patients were followed at the Pneumology Unit of Ospedale San Paolo, Milan, Italy. 
Asthma was diagnosed based on the occurrence of episodic wheezing, chest tightness 
and/or dyspnea and was objectively confirmed according to methacholine airway hyper-
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responsiveness (PC20 FEV1 <16mg/ml) and positive skin test to common allergens, as 
suggested by international guidelines (www.ginasthma.com). 
Exclusion criteria included pregnancy/lactation, active bleeding or conditions 
contraindicating treatment with antithrombotic drugs, previous TIA or stroke, age ≥75 
years, body weight <60 Kg, other indications for anti-thrombotic therapy, systolic blood 
pressure >180 mmHg or diastolic blood pressure >110 mmHg, use of non-steroid 
antinflammatory drugs (NSAIDs) in the previous 7 days. 
 
3.3  Measurements 
 
3.3.1 Mannitol bronchial challenge test  
 
In the mannitol bronchial challenge test, airway responsiveness was measured by 
bronchial provocation with dry powder mannitol (Osmohale™) using doses of mannitol 
up to 160 mg. The test was terminated when FEV1 decreased by at least 15% from 
baseline or after a cumulative mannitol dose of 635 mg. The provocative dose of 
mannitol causing 15% drop in FEV1 (PD15) was calculated by linear interpolation (6).  
3.3.2 Mediators of airway inflammation in sputum 
  
The mannitol challenge test was also used to induce sputum for airways 
inflammation assessment (7). Cell counts were performed in the induced sputum 
samples, to ensure adequacy for analysis. Thereafter, samples were centrifuged and 
supernatants stored for analysis of inflammatory markers (90).  
3.3.3 Fractional exhaled nitric oxide (FeNO) 
   
38 
 
 
Fractional exhaled NO (FeNO) was measured using the portable multi-gas 
analyzer (NIOX MINOH, Aerocrine, Sweden), in accordance with published guidelines 
(8). The portable analyzer ensures a constant expiratory flow of 50±5 ml/s, with an 
accuracy of ±10% (91). Measurement was performed with the patient in a sitting 
position, after resting ventilation, without nose clip, before performing the examination 
of pulmonary function and airway hyper-responsiveness. Mean values of 3 independent 
measurements were calculated for each patient at each time point.  
3.3.4 VASP phosphorylation assay 
 
The inter-individual variability of pharmacological response to drugs inhibiting 
the platelet P2Y12 receptor is high, particularly with clopidogrel (92, 93). For this reason, 
we elected to treat our patients with prasugrel, a third generation thienopyridine, which 
causes less variable inhibition of platelet P2Y12 than clopidogrel (66). Inhibition of 
platelet P2Y12 was evaluated by the Platelet Reactivity Index (PRI), using the 
vasodilator stimulated phosphoprotein (VASP) phosphorylation assay (Platelet VASP; 
Biocytex, Marseille, France) (92). The phosphorylation of vasodilator-stimulated 
phosphoprotein (VASP), an intraplatelet actin regulatory protein, by PGE1 is inhibited 
by the interaction of ADP with its P2Y12 receptor, which is targeted by P2Y12 antagonist. 
Briefly, the anticoagulated blood samples were incubated with PGE1 alone or in 
combination with ADP at room temperature for 10 min and fixed with 
paraformaldehyde. Platelets were then permeabilized with non-ionic detergent and 
labelled using a primary monoclonal antibody against 239-phosphorylated VASP 
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(16C2), followed by a secondary fluorescein isothiocynate-conjugated polyclonal goat 
anti-mouse antibody. The samples were analysed by dual colour flow cytometer (FC500, 
Beckman-Coulter) and the platelet population was identiﬁed from its forward and side 
scatter distribution; 10.000 platelets were gated. The analysis allowed to compare the 
two tested conditions and to evaluate the ability of ADP to inhibit VASP 
phosphorilation. The results were expressed as the platelet reactivity index (PRI) 
calculated using corrected mean fluorescence intensities (MFIc), reflecting VASP 
phosphorilation, of samples incubated with PGE1 alone or PGE1 plus ADP according to 
the following calculation: 
PRI = [(MFIc PGE1- MFIc (PGE1+ADP)) / MFIc PGE1] X 100 
3.4 Calculated Sample Size and Statistical Testing 
 
In the absence of data regarding the effectiveness of prasugrel  in reducing 
bronchial hyper-responsiveness, a sample size of 26 patients was calculated as needed 
to detect a decrease of 0.5 standard deviations in bronchial hyperresponsiveness with a 
power of 80%. All the examined variables followed a normal distribution according to 
the Kolmogorov-Smirnov test, thus allowing the use of parametric tests to analyse the 
data. Data are reported as means and 95% confidence intervals. Categorical data are 
reported as counts and percentages. Differences before and after each treatment were 
calculated by analysis of variance (ANOVA) for repeated measures. Post-hoc pairwise 
comparisons were performed with Least Significant Difference (LSD) test. All tests for 
statistical significance were two-tailed and P<0.05 was chosen as cut-off for statistical 
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significance. Analyses were carried out using SPSS for Windows 19.0 (SPSS Inc., 
Chicago, IL,USA).  
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4. RESULTS 
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4.1 Study patients’ characteristics 
 
We enrolled 26 patients (10 women, aged 43 years; 95%CI 39-48) in 10 months. 
Two women withdrew from the study due to asthma exacerbations during the second 
treatment (1 with placebo, 1 with prasugrel). Therefore, a complete set of data was 
available for 24 patients (Figure 6), whose characteristics are summarized in Table 1. 
Table 1. Characteristics of the patients enrolled in the study 
 
 
 
 
 
CI= 
confidence interval 
 
4.2 Primary Efficacy Measure 
 
The effects of prasugrel and placebo on the changes in airway hyper-
responsiveness, recorded as reduction of FEV1 (forced expiratory volume in 1-s) of at 
least 15% with the mannitol test induction, were compared by calculation of the 
difference between the increase in the average mannitol dosage from baseline to 
treatment. Differences in the provocative dose of mannitol causing a 15% drop in FEV1 
Characteristics N=24 
Sex, female (%) 8 (33) 
Age, years; mean (95%CI) 43 (38-48)  
Body Mass Index (BMI), mean (95%CI)  25.4 (24-27)  
Basal FEV1 (%), mean (95%CI) 90 (82-98)  
Duration of asthma in years,  mean (95%CI)   18 (13-24)  
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(PD15) before and after placebo or prasugrel were statistically significant (p<0.001, 
ANOVA for repeated measures). PD15 tended to increase from 142 mg (82-202) to 187 
mg (112-262)  after prasugrel (p=0.09), while it remained virtually unchanged after 
placebo (136 mg; 76-196 and 144 mg; 84-204, p=0.65) (Figure 7). Differences between 
PD15 values after prasugrel and those before and after placebo were borderline 
statistically significant  (p=0.050 and p=0.052). Delta-PD15 (PD15after treatment – 
PD15baseline) was 45.2 mg (-5-95) after prasugrel and 7.3 mg (-27-41) after placebo 
(p=0.16).  
 
Figure 7. Bar graph and individual dots of the PD15 (dose of mannitol causing a decrease in FEV1 of 
15%) in patients with allergic asthma before and 15 days after treatment with placebo or prasugrel (10 mg 
o.d.). P value:  ANOVA for repeated measures. Post-hoc analysis by Least Significant Difference test: 
before prasugrel vs. after prasugrel, p= 0.09; before placebo vs. after placebo, p= 0.65; after prasugrel vs. 
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before placebo, p= 0.050; after prasugrel vs. after placebo, p=0.052. The delta-PD15 (PD15after treatment – 
PD15baseline) values tended to be higher after prasugrel (45.2 mg; 95%CI -5-95) than after placebo (7.3 mg; 
95%CI -27-41) (p=0.16). 
4.3 Secondary Efficacy Measure 
 
4.3.1 Changes in measurement of nitric oxide expiration, as a surrogate marker 
of airway lung inflammation  
 
Fractional exhaled nitric oxide FeNO, a surrogate marker of eosinophilic airway 
lung inflammation, did not change significantly after treatment with prasugrel (from 
23;17-29  to 27;19-35  ppb; P=0.160) or placebo (from 25;18-32 to 28; 21-35 ppb; 
P=0.33).  
4.3.2 Changes in measurement of mediators of airway inflammation in sputum  
 
We could not perform the programmed measurement of markers of 
inflammation in induced sputum, because a complete set of 4 samples was obtained in 
one patient only, due to the inadequacy of either one or two samples of the remaining 
patients, based on the presence of insufficient numbers of cells at optical microscopy. 
4.3.3 Platelet VASP phosphorylation 
 
The Platelet Reactivity Index (PRI), measured by the VASP phosphorylation 
assay, decreased from a mean baseline value of 80% (77-83)  to 23% (17-29)  following 
prasugrel treatment (p<0.001), while it did not change following placebo treatment 
(78%; 74-82 vs 78%; 75-81 , P=0.88) (Figure 8). Three patients displayed PRI>50% 
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post-prasugrel, which is the cut-off value identifying poor responders to P2Y12-
antagonists (92). 
 
Figure 8. Bar graphs and individual dots of the effects of treatment with placebo or prasugrel (10 mg o.d.) 
of patients with chronic bronchial asthma for 15 days on platelet P2Y12-dependent reactivity (platelet 
reactivity index, PRI), measured by the Vasodilator-stimulated phosphoprotein (VASP) phosphorylation 
assay. P value: ANOVA for repeated measures. Post-hoc analysis by Least Significant Difference test: 
before prasugrel vs. after prasugrel, p< 0.001; before placebo vs. after placebo, p= 0.88; after prasugrel vs. 
before placebo, p<0.001; after prasugrel vs. after placebo, p<0.001 
 
 
 
   
46 
 
 
 
 
 
 
5. DISCUSSION AND CONCLUSIONS
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The main finding of this study is that in patients with mild chronic asthma, treatment with 
prasugrel tended to attenuate airway hyper-responsiveness, measured by the mannitol challenge test. 
The provocative dose of mannitol causing a 15% drop (PD15) in FEV1 tended to increase following 
treatment with prasugrel, although the difference with baseline values did not quite reach statistical 
significance (p=0.09). The design of this study virtually excludes the possibility that this difference 
is caused by variability among individuals. An increase in PD15 reflects a reduction in airway 
inflammation, because the mannitol test, like other indirect airway challenges, more closely reflects 
active airway inflammation than direct challenges, such as the metacholine test (94). The greater 
specificity of the mannitol test for detecting changes in airway hyper-responsiveness in asthma 
patients is likely explained by the fact that it mimics the normal pathophysiology of bronchial 
asthma, causing the release of mediators of bronchoconstriction (6). Although the increased PD15 
observed in our patients after prasugrel administration did not reach statistical significance, likely 
due to the small number of evaluable subjects and the wide inter-individual variability of baseline 
values, it does suggest that prasugrel may attenuate airway hyper-responsiveness in patients with 
allergic bronchial asthma, likely reducing active airway inflammation.  
Although P2Y12 is less promiscuous than P2Y1, which is the second platelet receptor for 
ADP, it is also expressed by cells other than the platelets (95). As a consequence, it remains to be 
established whether prasugrel affects bronchial hyper-responsiveness through inhibition of P2Y12 
on platelets or on other cells. The former hypothesis is supported by the results of experimental 
studies that demonstrated the important role of platelet P2Y12 in the recruitment of inflammatory 
cells in lungs of sensitized mice challenged with cysteinyl-LT (88, 89).  
The mechanism by which the platelet P2Y12 contributes to the effects of cysteinyl-LT is 
uncertain. Because LTE4 shows negligible activity at CysLT1R and CysLT2R, its biological effects 
are likely mediated by a third, elusive receptor, which was tentatively identified with P2Y12, based 
on computer modelling and the demonstration that LTE4 signals through P2Y12 in transfected cells 
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(96). However, more recently GPR99 was potentially identified as the elusive receptor for LTE4 
(86). Moreover, studies that demonstrated the important role played by platelet P2Y12 in LTE4- or 
LTC4-induced enhanced recruitment of inflammatory cells in the lungs of sensitized mice failed to 
show that CysLT interact directly with the platelet P2Y12, which might therefore play an indirect, 
albeit important role in the process (83, 88, 89). 
None of the patients enrolled in our study experienced pathological bleeding of any severity, 
in line with the evidence that the incidence of bleeding complications in patients treated with P2Y12 
inhibitors in monotherapy is low (97).  
In our study, FeNO, a surrogate marker of eosinophilic airway lung inflammation, did not 
change significantly after treatment with prasugrel or placebo. Therefore, FeNO may be a less 
sensitive marker than the mannitol inhalation test, which is considered a very sensitive means to 
detect bronchial hyper-responsiveness associated with airway lung inflammation.  
Unfortunately, we could not perform the programmed measurement of markers of 
inflammation in induced sputum, due to the difficulty to obtain adequate samples with a sufficient 
numbers of cells at optical microscopy.  
Due to the nature of our proof-of-concept study, we enrolled a small number of patients with 
allergic asthma and did not consider clinical end-points. Patients with severe, chronic allergic 
asthma on treatment with systemic steroids have higher levels of LTE4, compared with patients 
with mild/moderate asthma (98). Although patients with severe asthma might be more sensitive to 
therapeutic effect of P2Y12 antagonists, they were excluded from our study because concomitant 
treatment with steroids might influence the study end points.  
Evidence of the involvement of platelets in inflammatory processes in general and of platelet 
P2Y12 in the pathogenesis of allergic asthma stemmed from studies in animal models.The 
demonstration that P2Y12 variants are associated with lung function in a large family-based asthma 
cohort provided  the first human evidence  supporting a role for P2Y12 in this disorder (99). To the 
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best of our knowledge, our randomized, double-blind, placebo-controlled, cross-over study is the 
first to provide proof-of-concept that pharmacological inhibition of the platelet P2Y12 receptors may 
be useful in the treatment of patients with asthma. This hypothesis should be tested in randomized 
trials with clinical end-points. 
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